Table 2.
Median platelet count by use of concomitant ITP medication in the LTE
Observed platelet count, median, ×109/L | Rilzabrutinib monotherapy (n = 5) |
Rilzabrutinib + concomitant ITP medication (n = 11) |
---|---|---|
Main treatment period, baseline | 21 | 18 |
At LTE entry | 68 | 156 |
At LTE 3 mo | 90 | 94 |
At LTE 6 mo | 73 | 66 |